Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TSN084 Tablets in Patients With Advanced Malignant Tumors.
Conditions
Interventions
TSN084
Locations
1
United States
MD Anderson Cancer Center
Houston, Texas, United States
Start Date
February 18, 2022
Primary Completion Date
March 1, 2025
Completion Date
June 1, 2025
Last Updated
June 25, 2024
Lead Sponsor
Tyligand Bioscience (Shanghai) Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions